Usefulness of homeopathic medicines in COVID associated mucormycosis: A scoping review

Dr. Priya Singh

DOI: https://doi.org/10.33545/26164485.2022.v6.i2a.534

Abstract

Rationale: The term mucormycosis (Black fungus) is the common name given to different diseases caused by fungi of the order mucorales. An unforeseen upsurge in Covid associated mucormycosis cases was seen during the second wave of Covid-19 in India in the months of April-June. An attempt has been made to systematically map the research done as well as to identify the existing gaps in knowledge regarding Mucormycosis in the field of homoeopathy through a scoping review.

Objective: To determine and synopsize the scientific evidence for the usefulness of homeopathic medicines in post covid-19 mucormycosis.

Methodology: A web-based literature search from medical databases (Pub Med, Science direct) and google search engine was carried out till December 2021.

Results: Total 5 literature review works could only be traced, discussing the role of homoeopathy in mucormycosis. The articles are review woks, containing literature information on homoeopathic approach in mucormycosis. Available grey literature is handful, aggregate 5 in number. No in-vitro, in-vivo or clinical study to analyze the antifungal effects of homoeopathic medicines on Rhizopus/mucor species was obtainable.

Conclusion: It is evident that the usefulness and effectiveness of homoeopathy in patients of mucormycosis has not been explored. This scoping review may form an excellent foundation to bring to the fore of the researchers in homoeopathy across the globe to study and understand the role that homeopathic medicines can play in the treatment of mucormycosis and likewise, other opportunistic fungal infections. Following these suggestions, research conducted may determine the importance and value of homeopathy in mucormycosis which may lead to probable scope for a systematic review.

Keywords: Homoeopathy, Covid associated mucormycosis, rhino-orbito cerebral mucormycosis, and black fungus

Introduction

The Covid -19 virus disease is extant among us. During the second wave of the pandemic, there was a sudden rise in cases of mucormycosis in India. Mucormycosis colloquially known as the deadly 'Black Fungus' is a common name given to different disease caused by the fungi of the order mucorales of the subphylum Mucormycotina. Termed the name “mucormycosis” by the American pathologist R. D. Baker, it is a highly infectious, opportunistic fungal infection. The disease has an acute onset, rapid spread and produces serious angio-invasive involvement. It is a rarely occurring non-contagious disease having poor prognosis. These fungi moulds are ubiquitous, found in the soil, compost, decaying organic matter, air, etc. The infection is commonly seen in people having immune-compromised states. The high-risk patients include diabetics, patients with solid organ transplantation, having history of long-term corticosteroid use, neutropenia and iron overload. For people with weakened immune systems, mucormycetes spores cause an infection in the lungs or sinuses which spreads to other parts of the body [1, 2].

Paltauf coined the term 'Mycosis Mucorina' to a case of systemic infection with gastric and rhino-cerebral involvement. The first evidence of phycymycotic infection in a diabetic patient was done by J. E. Gregory and colleagues in 1943 [3]. Rhizopus oryzae is the most common causative organism and is culpable for almost 70% of all cases of mucormycosis [4] followed by Rhizopus microspores and Mucor circinelloides [5, 6]. Depending upon the site and organ involved, mucormycosis can be classified into Rhino-orbito cerebral (ROCM), Pulmonary, Cutaneous, Gastro-intestinal and disseminated forms. The rhino-orbito cerebral form of the disease was the most common presentation in most of the reported patients, followed by pulmonary mucormycosis. The patients complain symptoms of eye/facial pain, numbness
followed by conjunctival suffusion and blurry vision, periorbital edema and proptosis. The etiology for the rising incidence of zygomycosis/ mucormycosis in patients recovering from coronavirus disease was mostly linked to the injudicious use of corticosteroids with hyperglycemia, poor maintenance of humidifiers during oxygen therapy due to the overburden of the disease in hospital set-ups in India. Mucormycosis is an uncommon but serious infection that complicates the course of moderate to severe cases of Covid-19 [2]. The primary route of infection is though air spore inhalation. These spores deposit in the paranasal sinuses and the lungs. Other less common routes include consumption of contaminated food, or invasion through abraded skin. The fungus can even be introduced through direct access, through contaminated tongue depressors and wooden applicators being used to mix drugs given to immunocompromised patients. After nasal inoculation, the fungus rapidly progresses to the neighboring tissues, including the orbit, and sometimes to the brain. Mononuclear and polymorphonuclear phagocytes are the main defense weapons to fight mucormycosis. They kill Mucorales by generation of oxidative metabolites and cationic peptides ie, defensins. Subsequently, the neutrophils inhibit proliferation of the fungal spores. In case of immunocompromised patients, these fungal spores bypass the oxidative metabolites and defensins and spread through the endothelial lining and disseminates into the body leading to extensive necrosis (Black eschar). Due to the use of corticosteroids and immunosuppressants these effects are greatly enhanced. Corticosteroids cause impairment in the neutrophil migration, ingestion, and phagolysosome fusion. In case of infection through the COVID-19 virus, a sequential increase in the serum ferritin levels occur, thereby increasing the intracellular iron (a favorable growth factor for mucor). In patients with systemic ketoacidosis there is a temporary halt of transferring to bind iron therefore the free iron levels increase in serum favoring the growth of the fungus [7-10]. Diagnosis is based on a detailed patient history, identification of characteristic symptoms and thorough clinical evaluation. The most enabling diagnosis is through CT and particularly MRI. Other diagnostic tools are fungal culture, histopathology, MALDI-TOF mass spectrometry, etc. [11] the general treatment approach in mucormycosis is surgical debridement with antifungal regimen. Controlling underlying conditions such as hyperglycemia, diabetic ketoacidosis, and neutropenia is an important factor in treating the infection. Such an approach favors the prognosis of the disease. Post covid-19 confection with mucormycosis can be prevented by taking suitable measures. The patients must not be housed in dusty areas and must wear a good mask and take proper precautions with maintaining a strict hand hygiene. There must be strict control of blood sugar. Judicious use of steroids with strict compliance to correct timing, correct dose, and duration by the treating physician. Strict vigilance over the use of only sterile/distilled water for humidifiers during oxygen therapy is recommended. All the hospital equipment’s used for oxygenation such as nasal prongs, nasal cannula, masks for ventilation, etc. must be sterilized before each use and every day [12]. The incidence of covid associated mucormycosis cases reported in India till 7 June,2021 were 28200 with a contribution of approximately 70% cases globally [13]. Even prior to the coronavirus pandemic, mucormycosis was already far more prevalent in India than any other country. It is estimated to affect 14 per 100,000 people in India as compared to 0.06 per 100,000 in Australia [14]. Previous study reports from the hospitals all over the country have revealed presence of heavy mould spore counts in the hospital air. The chief reason is due to the hot, humid and tropical climate in India [5]. The rationale of the review was to systematically map the research done as well as to identify the existing gaps in knowledge regarding Mucormycosis in the field of homeopathy. Based on which, following research questions were formulated:
1. What is known from homeopathic literature about the treatment of mucormycosis?
2. Are there any published research work to establish the role of homeopathic drugs in treatment of cases of mucormycosis?

The objective of the study was to identify and summarize the scientific evidence for the usefulness of homeopathic medicine in post-Covid mucormycosis.

Materials and Methods
Scoping reviews are conducted to map existing literary work throughout a certain topic and to recognize the gaps and hereafter the research needs. They are used essentially in situations where little is known about a particular topic. Scoping reviews are supposed to be carried out systematically following an iterative approach and report the findings parochially to explore a topic. This scoping review was conducted following the PRISMA Extension for scoping review guidelines 2018. A web-based literature search from medical databases (Pub Med, Science direct) and google search engine was carried out till December 2021. (Figure 1)

The inclusion and exclusion criteria were

Inclusion criteria
1. Records where details of role of homoeopathic medicines in mucormycosis were given
2. Records with full text available were included.
3. Records published in English language were included.

Exclusion criteria
1. Records where details on homoeopathy or homeopathic medicines were not available were excluded.
Result

Total 5 literature review works could only be traced, discussing the role of homoeopathy in mucormycosis (Table 1). Available grey literature is handful, aggregate 5 in number. (Table 2). No in-vitro, in-vivo or clinical study to analyze the antifungal effects of homoeopathic medicines on rhizopus/mucor species was obtainable.

Table 1: List of peer articles retrieved through web search

| Author               | Year | Journal                                      | Aim                                                                 | Method   |
|----------------------|------|----------------------------------------------|----------------------------------------------------------------------|----------|
| Javed D, Dixit AK, Vats H et al. [15] | 2021 | International Journal of Health Sciences and Research | To investigate the role of Ayurveda and Homoeopathy in the treatment of mucormycosis | Narrative review |
| S.R. Sharma, Bindu Sharma [16] | 2021 | Homoeopathic Links                           | N/A                                                                 | Editorial |
| Singh M. [17]        | 2021 | International Journal of Science & Research   | To study Mucormycosis and its homeopathic approach                   | Literature review |
| Gond BP. [18]        | 2021 | International Journal of Homoeopathic Sciences | To get an overview of etiopathogenesis of Mucormycosis and its homoeopathic approach | Literature review |
| Dwivedi AK. [19]     | 2021 | International Journal of Scientific Review    | How homoeopathic medicines can help treat /cure Black fungus/ Mucormycosis in patients under Allopathic treatment | Literature review |

Table 2: List of Grey literature available

| Organisation             | Author               | Publication                                                                 | Date       | Notes                                                                 |
|--------------------------|----------------------|----------------------------------------------------------------------------|------------|-----------------------------------------------------------------------|
| Ministry of AYUSH, GOI [20] | Not applicable       | Information for Homoeopathy Practitioners for Symptomatic Management of Suspected and Diagnosed cases of Mucormycosis | May 21, 2021 | Includes general guidelines for Homoeopathic doctors to provide symptomatic management in cases of Mucormycosis |
| Dr Willmar Schwabe [21]  | Dr. Aditi Sharma     | White versus Black Fungus: Is white Fungus more dangerous than Black Fungus | July 14, 2021 | Provides information on both white fungus and black fungus, gives a comparison between the two fungus groups with indications of homoeopathic medicines |
| Homeocare4u [22]        | Dr. Vishnu Singh     | Top 5 homoeopathic remedies for Black Fungus or Mucormycosis               | Not mentioned | Give a list of homoeopathic medicines for mucormycosis based on the general symptoms |
| Homoeopathic Dr Makkar Family Clinic [23] | Dr. G. S. Makkar Sukhmani | Mucormycosis Black Fungus Zygomycosis Homoeopathic treatment | Not mentioned | Mentions a detailed description of mucormycosis including the pathogenesis and symptomatology. Also details the group of homoeopathic medicines suitable in such infections |
| Souls [24]              | Dr. Divya Mishra     | Mucormycosis management with a Homoeopathic approach                       | June 8, 2021 | Provides a brief history, current scenario and types of mucormycosis with a list of homoeopathic medicines in mucormycosis |

The common medicines reviewed for their utility in mucormycosis, as per the literature retrieved from the peer review studies have been enlisted (Table 3).
Discussion
It was evident from the results of the review, that the role of homeopathic medicines in mucormycosis is unfathomed. The review could not trace any clinical studies (RCTs, case series/case reports) and observational studies. The articles accessible were solely review of the mucormycosis basic pathophysiology and approach of homoeopathy in treating the disease. Indications of homeopathic medicines from textbooks have been illustrated in the reviews based on symptom similarity. Hypothetically, to conduct studies on patients suffering from mucormycosis are certainly difficult owing to the rapid and fulminating growth of the fungus and availability of isolated infections. This is the probable reason for the scarcity of evidence on effectiveness of homeopathic medicines in cases of mucormycosis clinically. However, the in-vitro effects have also not been observed.

Till date, the extent of available research studies with homeopathic medicines in case of fungal infections is limited to the effects of inhibiting fungal growth, in-vitro. Few clinical trials establishing the role of homeopathic medicines on the common dermatophytes and candida infections have been done. As perceptible from past works, homeopathic medicines possess antifungal properties. Sharma B. in 2019, conducted an in-vitro study on Candida albicans to study the effects of homeopathic mother tinctures of Syzygium jambolanum, Ficus religiosa, Ocimum sanctum and Allium cepa. Conventional drug Ketoconazole (10 µg/ml) was used as control. The fungal sample were taken from 60 patients suffering from Candida infection. The fungal culture was procured as lyophilised freeze dried culture strain and was used to evaluate the antifungal activity using the agar disc diffusion method. The study concluded the antifungal properties of these drugs by measuring the zone of inhibition. The homeopathic mother tincture S. Jambolanum had maximum zone of inhibition, even more than Ketoconazole.[25]

Shinde CH, Anand PK, Kunchiraman BN et al, 2018 tested the in-vitro effects on C.albicans through anti-candida assay using agar-diffusion method, minimum inhibitory concentration values and germ tube inhibition method. The homeopathic medicines Azadirachta indica, Cinchona officinalis, Zinncum metallicum, Iodium, Selenium, Sulphur, Acidum Benzoicum, Phosphorus, Acidum Sulphuricum and Zingiber officinale were tested in 6C, 12C, 30C, 200C, 1M potencies for their effects.[26] Similar previous studies by different researchers to analyze the in-vitro effects of homeopathic medicines in various potencies have concluded results favoring the use of homeopathic medicines on Candida albicans. The drugs that have been worked on are Sulphur, Holarrhena antidysenterica, Eucalyptus globulus, Apis mellifica, Kali iodatum, Mezereum, Petroleum, Tellarrium, Sulphur iodatum, Graphites, Sepia, Silica and Thuja occidentalis [27-29].

In another study on the commonly occurring Aspergillus niger, homeopathic medicines Allium cepa, Allium sativum, Caesalpinia bonducella, Calotropis gigantean, Cassia angustifolia, Eucalyptus globulus, Ficus religiosa, Holarrhena antidysenterica, Kalmia latifolia, Ocimum sanctum, Ruta graveolens, Syzygium jambolanum, Thuja occidentalis, Terminalia chebula, and Zingier officinalis have been investigated for their antifungal properties[30]. Few more such studies on other fungus have been carried out showing effective results with homeopathic drugs in in-vitro models. A similar approach may be beneficial in elucidating the utility of homeopathic medicines in Rhizopus and other mucormycosis causing fungal species as well.

Conclusion
Homoeopathy is a well-established form of alternative therapy globally. Homoeopathic Materia medica is enriched with medicines that help to cure any disease occurring in nature. Being a rarely occurring infection, much evidence on the role of homoeopathy in mucormycosis has not been yet established. As fungal infections are so common in India due to hot and humid climate, more work in homeopathy will certainly open doors to some unexplored arenas. Mucormycosis, being a rapidly progressing disease and having high incidence in India, the study of homeopathic drug action on mucormycosis will be advantageous both for the patients and the system of medicine. In such a global crisis where, every individual is affected in some way, use of natural healing art of homoeopathy can help rejuvenate the patients and the system of medicine. In such a global crisis where, every individual is affected in some way, use of natural healing art of homoeopathy can help rejuvenate.

Conflict of interest: The author declares no conflict of interest.

References
1. Slavin M, Thursky K. The Conversation. What is mucormycosis, the fungal infection affecting COVID patients in India? [Internet]. 2021 May 13 [cited 2021 Jun 21] Available from: https://thecconversation.com/what-is-mucormycosis-the-fungal-infection-affecting-covid-patients-in-india-160707
2. Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, et al. Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature. Mycopathologia [Internet]. 2021 May [cited 2021 Jun 26];186(2):289-298. Available from: https://pubmed.ncbi.nlm.nih.gov/33544266/ DOI:
24. souls

25. Sharma B. Assessment of anti-candidial activity of different homoeopathic medicines against Candida albicans. Int J Hom Sci [Internet]. 2019 [cited 2021 Nov 16];3(3):35-37. Available from: https://www.homoeopathicjournal.com/articles/93/3-3-9-796.pdf

26. Shinde CH, Anand PK, Kunchiraman BN, et al. In vitro study for the anti-candida activity of homoeopathic medicines against candida albicans. Int J Health Sci Res. [Internet] 2018 [cited 2021 Oct 22];8(9):57-61. Available from: https://www.researchgate.net/publication/333421631_In_Vitro_Study_for_the_Anti_Candida_Activity_of_Homoeopathic_Medicines_against_Candida_Albicans

27. Kumar SS, Shivaprasad K. Activity of homoeopathic drug sulphur with different potencies on lawn culture of escherichia coli and candida albicans–topically an in-vitro evaluation. Int J Hom Sci [Internet] 2018 [cited 2021 Nov 11];2(4):23-27. Available from: https://www.homoeopathicjournal.com/articles/44/2-4-6-929.pdf

28. Prajapati S, Sharma M, Gupta P, Kumar M, Dwivedi B, Arya BS. Evaluation of antifungal activity of different homoeopathic mother tinctures against Candida albicans. Indian J Res Homoeopathy [Internet] 2017 [cited 2021 Sept 8];11:237-43. Available from: https://www.ijrh.org/text.asp?2017/11/4/237/221957

29. Gupta G, Srivastava AK, Gupta N, Gupta G, Mishra S. Anti-candidal activity of homoeopathic drugs: An in-vitro evaluation. Indian J Res Homoeopathy [Internet] 2015 [cited 2021 Nov 19];9:79-85. Available from: https://www.ijrh.org/text.asp?2015/9/2/79/159522

30. Prajapati S, Sharma M, Kumar A, Gupta P, Dwivedi B, Arya BS, et al. Antimicrobial activity of different homoeopathic drugs and their potencies against 'Aspergillus niger' In vitro. Indian J Res Homoeopathy [Internet] 2019 [cited 2021 Dec 13];13:150-8. Available from: https://www.ijrh.org/text.asp?2019/13/3/150/268518